Sign in

    Andrew Kessner

    Research Analyst at William O'Neil & Co.

    Andrew Kessner is an Equity Research Analyst at William O’Neil & Co., specializing in equity research with a focus on the cannabis and aerospace sectors. He has covered companies such as Aurora Cannabis, iAnthus Capital Holdings, and commented publicly on Boeing, delivering timely market insights and research commentary. Kessner began his career as an Equity Research Associate at Cowen & Co. in 2018 before joining William O’Neil & Co. later that year; he served in the role from 2018 to at least 2020, building a profile as a quoted expert in both Bloomberg and Reuters. He holds a robust background in financial analysis though specific securities licenses or FINRA registration details are not readily available.

    Andrew Kessner's questions to iANTHUS CAPITAL HOLDINGS (ITHUF) leadership

    Andrew Kessner's questions to iANTHUS CAPITAL HOLDINGS (ITHUF) leadership • Q1 2019

    Question

    Andrew Kessner of William O'Neil & Co. followed up on Florida, asking about the current sales mix of flower versus other products. He also inquired about the company's outlook for New York, specifically whether they see a medical market expansion or full adult-use as more likely in the near term.

    Answer

    CEO Hadley Ford stated that flower sales in Florida were a little over 50% in May but cautioned that supply would be limited over the summer due to infrastructure upgrades. Regarding New York, he explained that while adult-use is possible, the political situation is complex, and the company believes any expansion that allows for broader retail distribution ultimately plays into their brand-focused strategy.

    Ask Fintool Equity Research AI